Abstract:Abstract Background CD4+ memory T cells (Tmem) drive chronicity of inflammation in Crohn’s disease (CD) and ulcerative colitis (UC). Treatments specifically targeting T cells effectively induce disease remission. However, due to disease heterogeneity and possibly variation in the Tmem response, not all patients achieve or maintain remission. As such, strategies are needed to identify and monitor the therapeutic target, i.e. the inflammatory Tmem response, in individual patients. Monitoring has been hampered by the large variety in both protective regulatory and pathogenic inflammatory Tmem phenotypes, thus, common denominators need to be identified to distinguish all inflammatory from all regulatory intestinal Tmem populations in individual patients. We have shown that the coinhibitory receptor T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is a common denominator identifying regulatory gut-homing Tmem. TIGIT shares its ligands with the costimulatory receptor CD226. While TIGIT ligation inhibits Tmem responses, CD226 engagement enhances Tmem activity. We hypothesize that TIGIT and CD226 differentiate the protective regulatory from the pathogenic inflammatory intestinal Tmem in individual IBD patients. Methods We studied CD38+CD62Lneg gut-homing Tmem in blood of therapy-naive pediatric IBD patients (CD n=59; UC n=32; IBD negative controls (IBDneg) n=24). Results In a subgroup of CD, but not UC patients, frequencies of regulatory TIGIT+ gut-homing Tmem at diagnosis were strongly reduced compared to IBDneg. Of these CD patients with low TIGIT frequencies, a significantly higher proportion had severe disease, defined as failing to achieve remission after 6 months or having a disease relapse within 1 year, compared to CD with normal TIGIT frequencies. As TIGIT is a common denominator for regulatory cells, we hypothesized that gut-homing Tmem without TIGIT (TIGITneg) contained inflammatory Tmem. Indeed, in CD, the TIGITneg Tmem population contained increased frequencies of pathogenic IFNg+IL-17+-double-producing cells compared to IBDneg. As TIGIT and CD226 frequencies inversely correlated (R=-0.78, p=4.8e-05) in CD patients, we assessed whether additional monitoring of CD226 could be used to more precisely identify and monitor inflammatory Tmem in CD. As anticipated, TIGITnegCD226+ gut-homing Tmem frequencies significantly increased in CD patients compared to UC patients and IBDneg. TIGITnegCD226+ Tmem were more proliferative and more activated compared to IBDneg, indicating increased inflammatory function. Conclusion These data establish that TIGIT and CD226 can be used to enumerate and differentiate the protective regulatory from the pathogenic inflammatory gut-homing Tmem in individual IBD patients, and to identify patients with severe disease.

Exclusive increase of CX3CR1+CD28−CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes

Tenascin-C is Increased in Inflammatory Bowel Disease and is Associated with Response to Infliximab Therapy

Immune Regulatory Mechanisms of CD177+ Neutrophils in the Pathogenesis of Inflammatory Bowel Disease

Fbxw7 Increases CCL2/7 in CX3CR1(hi) Macrophages to Promote Intestinal Inflammation

Increased expression of fractalkine and its receptor CX3CR1 in canine inflammatory bowel disease and their possible role in recruitment of intraepithelial lymphocytes

Expressions of KIR2DL1 and KIR2DL3 in Peripheral Blood and Intestinal Tissue in Patients with Inflammatory Bowel Disease

CD177+ Neutrophils and Its Correlation with Mucosal Impairment in Patients with Inflammatory Bowel Disease

Immune Regulation of Interleukin-23 on Peripheral Blood Natural Killer Cell in Patients with Inflammatory Bowel Disease

Potential Role of NK Cells in the Pathogenesis of Inflammatory Bowel Disease

CD99 Refers to the Activity of Inflammatory Bowel Disease

Increased Expression of Interleukin-23 Induces Proinflammatory Cytokine Secretion in Inflammatory Bowel Disease

Expression of Ikir-Hla-Cw in Patients with Inflammatory Bowel Disease

Chemokines as Novel Therapeutic Targets for Inflammatory Bowel Disease

Significance of interleukin-27 expression in the intestinal mucosa of patients with inflammatory bowel disease

The Increased Expression of IL-23 in Inflammatory Bowel Disease Promotes Intraepithelial and Lamina Propria Lymphocyte Inflammatory Responses and Cytotoxicity.

Increased Expression of CCL20 in Human Inflammatory Bowel Disease

[Relationship Between Expression of Inhibitory Killer Cell Immunoglobulin-Like Receptor HLA-Cw Ligand and Susceptibility to Inflammatory Bowel Disease].

Expressions and Significance of CXC Chemokine Receptor Type 2 and Interleukin-8 in Patients with Inflammatory Bowel Disease

DOP32 CD226+TIGITneg expression identifies pathogenic inflammatory CD4+ memory T cells in severe Crohn’s Disease patients, opening up opportunities for patient-tailored treatment strategies

Dynamic role of macrophage CX3CR1 expression in inflammatory bowel disease

NKT Cells Mediate the Recruitment of Neutrophils by Stimulating Epithelial Chemokine Secretion During Colitis.